Grufity logoGrufity logo

RPTX

16.06USD+0.20(+1.26%)Market Closed

Repare Therapeutics Inc.

Market Summary

USD16.06+0.20Market Closed
1.26%

RPTX Stock Price

RSI Chart

Valuation

Market Cap

654.6M

Price/Earnings

-4.96

Price/Sales

79.43

Price/Cashflow

-5.86

MarketCap/EBT

-4.92

Price/Sales

Profitability

EBT Margin

-1614.74%

Return on Equity

-58.55%

Return on Assets

-42.86%

Fundamentals

Revenue

Revenue Y/Y

40.4K%

Revenue Q/Q

99.28%

Earnings

Earnings (TTM)

-132.0M

Earnings Y/Y

-44.79%

Earnings Q/Q

-9.6%

Price Action

52 Week Range

27.40
(Low)(High)

Last 7 days

-11.4%

Last 30 days

8.4%

Last 90 days

33.4%

Trailing 12 Months

-38.5%

Financial Health

Current Ratio

7.35

Investor Care

Shares Dilution (1Y)

0.54%

Diluted EPS (TTM)

-0.74

Peers (Alternatives to Repare Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.4T
394.3B
-0.67% -8.01%
23.66
5.99
7.79% 5.41%
1.8T
203.1B
7.29% -26.07%
25.2
8.66
15.22% 2.81%
1.3T
282.1B
2.93% -33.48%
18.7
4.44
17.94% -5.14%
952.9B
502.2B
-19.24% -47.82%
84.16
1.9
9.66% -56.89%
MID-CAP
2.5B
8.6B
6.97% -44.81%
-5.69
0.31
76.30% -20.89%
SMALL-CAP
1.9B
628.4M
4.90% -64.68%
-4.08
3.1
64.35% -18.14%
1.9B
1.6B
1.73% 6.73%
12.45
1.23
81.91% 208.48%
1.5B
-
15.46% -69.17%
-0.54
1.95
-4.11% -144.36%
1.4B
40.0M
-23.89% -77.58%
-1.84
34.64
34.91% -55.12%
1.0B
247.8M
5.73% -20.09%
-17.78
4.46
23.41% -194.70%
1.0B
412.4M
16.46% -28.89%
-153.63
2.47
51.09% -102.33%
988.1M
439.7M
-14.05% -83.16%
-2.97
2.13
-5.64% -199.38%
861.5M
1.2B
1.09% -47.19%
2.31
0.73
7.66% 583.60%
551.2M
2.2M
2.03% -70.95%
-1.55
343.43
-72.60% -50.32%

Financials for Repare Therapeutics

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
RevenueNaN%nullnull7,8427,600964
Operating Expenses5.1%149,407142,218129,751116,26097,861
  S&GA Expenses4.2%32,26030,95229,75526,21323,369
  R&D Expenses5.3%117,147111,26699,99690,04774,492
Earnings Before Taxes80.5%-25,972.00-133,087.00-121,757.00-108,586.00-96,701.00
Net Income-9.8%-132,032.00-120,248.00-106,908.00-93,881.00
* denotes actual numbers (not divided by Thousands)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets32.8%409308337369296
  Current Assets34.8%391290319351280
    Cash Equivalents-43.7%155276305334261
  Net PPE-8.6%55564
Liabilities25.3%10383788077
  Current Liabilities56.9%6239343523
Shareholder's Equity35.6%306226259288218
  Retained Earnings26.7%-207.65-283.12-245.02-210.27-181.98
  Additional Paid-In Capital18.1%3227231814
Accumulated Depreciation-3----
Shares Outstanding0.1%4242424237
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations108.3%9,221-111,710.00-101,575.00-85,796.00-78,005.00
  Share Based Compensation8.0%18,44917,08915,52712,8299,939
Cashflow From Investing-12317.8%-210,234.00-1,693.00-501.00-1,676.00-10,525.00
Cashflow From Financing-0.1%95,27795,37195,61595,5571,284

Risks

What is the probability of a big loss on RPTX?

97.7%


Probability that Repare Therapeutics stock will be more than 20% underwater in next one year

96.1%


Probability that Repare Therapeutics stock will be more than 30% underwater in next one year.

46.9%


Probability that Repare Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RPTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Repare Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on RPTX

Which funds bought or sold RPTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-24,000
197,000
-%
2022-11-15
ALGERT GLOBAL LLC
NEW
-
344,000
344,000
0.02%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
FRED ALGER MANAGEMENT, LLC
ADDED
6.76
-24,000
295,000
-%
2022-11-15
HERSHEY TRUST CO
SOLD OFF
-100
-179,000
-
-%
2022-11-15
STATE STREET CORP
ADDED
1.23
-90,000
649,000
-%
2022-11-14
Affinity Asset Advisors, LLC
SOLD OFF
-100
-4,494,000
-
-%
2022-11-14
ROYAL BANK OF CANADA
-
-
-1,000
8,000
-%
2022-11-14
BVF INC/IL
-
-
-15,423,000
100,582,000
4.16%
2022-11-14
VANGUARD GROUP INC
-
-
-129,000
895,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying RPTX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own RPTX

Repare Therapeutics News

MarketBeat

Repare Therapeutics Inc. Forecasted to Post FY2022 Earnings of ($0.88) Per Share (NASDAQ:RPTX).7 days ago

RPTX Fair Value

Recent SEC filings of Repare Therapeutics

View All Filings
Date Filed Form Type Document
Nov 09, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for RPTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-06-13
BVF PARTNERS L P/IL
BOUGHT
1,898,820
12.73
149,161
-
2022-06-06
Jerel Davis
ACQUIRED
-
-
9,101
-
2022-06-06
Versant Ventures V, LLC
ACQUIRED
-
-
10,099
-
2022-06-06
Versant Vantage I, L.P.
ACQUIRED
-
-
151,202
-
2022-06-06
Versant Ventures V, LLC
SOLD
-
-
-710,099
-
2022-06-06
Versant Ventures V, LLC
SOLD
-
-
-141,103
-
2022-06-06
Jerel Davis
ACQUIRED
-
-
151,202
-
2022-06-06
BVF PARTNERS L P/IL
BOUGHT
90,751.9
13.2118
6,869
-
2022-06-06
Versant Ventures V, LLC
ACQUIRED
-
-
141,103
-
2022-06-03
Versant Ventures V, LLC
SOLD
-9,188,780
12.2517
-750,000
-

1–10 of 50

Lloyd M. Segal
150
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

RPTX Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Collaboration agreements$ 112,545$ 278$ 113,632$ 723
Operating expenses:    
Research and development, net of tax credits31,24225,36189,17562,075
General and administrative7,9046,59624,62118,574
Total operating expenses39,14631,957113,79680,649
Income (loss) from operations73,399(31,679)(164)(79,926)
Other income (expense), net    
Realized and unrealized gain (loss) on foreign exchange12633250(92)
Interest income2,027532,700155
Other expense(37)(7)(56)(21)
Total other income, net2,116792,89442
Income (loss) before income taxes75,515(31,600)2,730(79,884)
Income tax recovery (expense)(54)708(119)1,266
Net income (loss)75,461(30,892)2,611(78,618)
Unrealized loss on available-for-sale marketable securities(524)0(524)0
Total other comprehensive loss(524)0(524)0
Comprehensive income (loss)$ 74,937$ (30,892)$ 2,087$ (78,618)
Net income (loss) per share attributable to common shareholders--basic$ 1.80$ (0.83)$ 0.06$ (2.12)
Net income (loss) per share attributable to common shareholders-diluted$ 1.71$ (0.83)$ 0.06$ (2.12)
Weighted-average common shares outstanding-basic41,945,61737,122,66841,902,55437,026,116
Weighted-average common shares outstanding-diluted44,177,37637,122,66844,160,48137,026,116

RPTX Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
CURRENT ASSETS:  
Cash and cash equivalents$ 155,191$ 334,427
Marketable securities215,1627,439
Research and development tax credits receivable2,9072,580
Income tax receivable6290
Collaboration revenue receivable9,6260
Other receivables1,447654
Prepaid expenses5,6356,314
Total current assets390,597351,414
Property and equipment, net4,6835,604
Operating lease right-of-use assets5,9047,491
Other assets497586
Deferred tax assets7,4773,620
TOTAL ASSETS409,158368,715
CURRENT LIABILITIES:  
Accounts payable9,3452,302
Accrued expenses and other current liabilities15,61518,622
Operating lease liability, current portion2,1271,721
Deferred revenue, current portion34,78411,921
Income tax payable0523
Total current liabilities61,87135,089
Operating lease liability, net of current portion3,7675,592
Deferred revenue, net of current portion37,74439,613
TOTAL LIABILITIES103,38280,294
SHAREHOLDERS’ EQUITY  
Preferred shares, no par value per share; unlimited shares authorized as of September 30, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding as of September 30, 2022, and December 31, 2021, respectively00
Common shares, no par value per share; unlimited shares authorized as of September 30, 2022 and December 31, 2021; 41,961,510 and 41,850,162 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively481,782480,699
Additional paid-in capital32,17317,988
Accumulated other comprehensive loss(524)0
Accumulated deficit(207,655)(210,266)
Total shareholders’ equity305,776288,421
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$ 409,158$ 368,715